Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from FibroGen

Stock Market Rebounds Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review

The market rally had a strong week, with the major indexes rebounding toward 2023 highs and many stocks flashing buy signals.

Investors Business Daily

FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug

FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug

FibroGen reported a second failure for its lead asset on Monday, and FGEN stock crashed to its lowest-ever point.

Investors Business Daily

FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost

FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost

FibroGen's leading drug failed in a final-phase study of Duchenne muscular dystrophy patients on Wednesday, leading FGEN stock to dive.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90

FibroGen shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

12 Health Care Stocks Moving In Tuesday's Intraday Session

Earnings Outlook For FibroGen

FibroGen (NASDAQ:FGEN) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that FibroGen will report an earnings per share (EPS) of $-0.83.

inkl

Read news from The Economist, FT, and more,
with one subscription

FibroGen's Earnings: A Preview

FibroGen's Earnings: A Preview

FibroGen (NASDAQ:FGEN) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that FibroGen will report an earnings per share (EPS) of $-0.66.

Organisations

US Federal Reserve

Constellation Brands

European Medicines Agency

Medicines and Healthcare products Regulatory Agency

SmileDirectClub

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Pulmonary Fibrosis

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

253,912 stories

107,390 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play